Rebound of multiple sclerosis activity after fingolimod withdrawal due to planning pregnancy: Analysis of predisposing factors

•3 (42%) patients suffered rebound after fingolimod cessation for pregnancy planning.•Pregnancy failed to halt such exaggerated inflammatory activity.•New-borns were delivered healthy despite using steroids throughout pregnancy.•Lymphocyte count

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Multiple sclerosis and related disorders 2020-02, Vol.38, p.101483-101483, Article 101483
Hauptverfasser:	Sepúlveda, Maria, Montejo, Carmen, Llufriu, Sara, Sola-Valls, Nuria, Reyes, David, Martinez-Lapiscina, Elena H., Zubizarreta, Irati, Pulido-Valdeolivas, Irene, Martinez-Hernandez, Eugenia, Ariño, Helena, Baños, Nuria, Saiz, Albert, Blanco, Yolanda
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Female Fingolimod Fingolimod Hydrochloride - administration & dosage Humans Immunosuppressive Agents - administration & dosage Live Birth Lymphocytes Magnetic Resonance Imaging Multiple sclerosis Multiple Sclerosis - blood Multiple Sclerosis - drug therapy Multiple Sclerosis - pathology Multiple Sclerosis - physiopathology Pregnancy Pregnancy Complications - blood Pregnancy Complications - drug therapy Pregnancy Complications - pathology Pregnancy Complications - physiopathology Rebound Reproductive Behavior Retrospective Studies Severity of Illness Index Symptom Flare Up Time Factors Withdrawal
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	•3 (42%) patients suffered rebound after fingolimod cessation for pregnancy planning.•Pregnancy failed to halt such exaggerated inflammatory activity.•New-borns were delivered healthy despite using steroids throughout pregnancy.•Lymphocyte count
ISSN:	2211-0348 2211-0356
DOI:	10.1016/j.msard.2019.101483